Novavax told by FDA to conduct additional study for COVID vaccine - report

Carsten Koall/Getty Images News The U.S. FDA is asking Novavax ( NASDAQ: NVAX ) to conduct an additional randomized, controlled study of its COVID-19 vaccine before it will consider approving it.

The prospect is a major setback for the biotech as it would be costly for the.